Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 5665 Download: 375 Web of Science: 17 Crossref: 21

Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications

Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, Beatriz San-Miguel, María J. Tuñón, Javier González-Gallego, José L. Mauriz

Clin Mol Hepatol. 2023;29(2):293-319. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0425

View: 4327 Download: 114 Web of Science: 5 Crossref: 5

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan

Clin Mol Hepatol. 2023;29(2):277-292. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0212

View: 6912 Download: 519 Web of Science: 18 Crossref: 22

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 5175 Download: 311 Web of Science: 10 Crossref: 10

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(2):252-262. Published online March 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0099

View: 4537 Download: 247 Web of Science: 13 Crossref: 17

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(2):242-251. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0102

View: 4727 Download: 224 Web of Science: 3 Crossref: 5

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective

Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):230-241. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0421

View: 5838 Download: 372 Web of Science: 9 Crossref: 10

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 5633 Download: 244 Web of Science: 7 Crossref: 10

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 6370 Download: 449 Web of Science: 31 Crossref: 30

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective

Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi

Clin Mol Hepatol. 2023;29(2):197-205. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0404

View: 4526 Download: 233 Web of Science: 12 Crossref: 11

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 7579 Download: 166 Web of Science: 6 Crossref: 11

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 3704 Download: 134 Web of Science: 3 Crossref: 4

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 5465 Download: 279 Web of Science: 9 Crossref: 8

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 4284 Download: 308 Web of Science: 17 Crossref: 17

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4211 Download: 168 Web of Science: 19 Crossref: 22

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 14179 Download: 1,111 Web of Science: 72 Crossref: 91

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 5031 Download: 231 Web of Science: 13 Crossref: 15

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 4052 Download: 181 Web of Science: 11 Crossref: 12

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 5518 Download: 273 Web of Science: 15 Crossref: 18

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 5150 Download: 304 Web of Science: 20 Crossref: 23

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 5813 Download: 280 Web of Science: 8 Crossref: 10

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4129 Download: 198 Web of Science: 11 Crossref: 12

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4218 Download: 222 Web of Science: 17 Crossref: 17

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 4813 Download: 272 Web of Science: 7 Crossref: 8

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 4609 Download: 233 Web of Science: 21 Crossref: 22

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 3785 Download: 106

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 10806 Download: 452 Web of Science: 92 Crossref: 119

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 5935 Download: 314 Web of Science: 6 Crossref: 7

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 3479 Download: 103 Web of Science: 3 Crossref: 4

Special thanks

Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S4-S4. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0010

View: 1921 Download: 38

Viewed By 5660	MAFLD: How is it different from NAFLD?
Viewed By 5579	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5384	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5331	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4984	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Topics